A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.

← catalyst calendar

NCT07567781

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.

Phase

Phase 1

Status

Active, not recruiting

Study type

Interventional

Design

Na · None · Basic science

Enrollment

12estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-04-30

actual

When the study began enrolling

Primary completion

Jul 2026

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Jul 2026

estimated

The whole study's end, after follow-up

First posted

2026-05-05

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-20

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Healthy Volunteers

Interventions

Drug: ABBV-722
Drug: Midazolam
Drug: Metformin
Drug: Digoxin
Drug: Pitavastatin
Drug: Sitagliptin

Primary outcomes

what the primary-completion date above is the date OF

Number of Participants with Adverse Events (AEs)

measured Up to 56 Days

Maximum Observed Plasma Concentration (Cmax) of Midazolam, 1-OH Midazolam, Digoxin, Pitavastatin, Sitagliptin, and Metformin.